November 20th, 2013
AHA.13: Good until the End
Seth Shay Martin, MD
On the last afternoon at AHA.13, a poster on an experimental preventive treatment catches the eye of a cardiology Fellow .
November 19th, 2013
Big Impact from a Little-Publicized Session at AHA.13
Saurav Chatterjee, MD
A Fellow wonders about a “fabulous” presentation — why was it held at a relatively early hour and in one of the smaller meeting rooms?
November 19th, 2013
AHA 2013: Reflections on My Wish List
Vimal Ramjee, MD
A fellow describes his wish list for conferences that better meet the needs of trainees.
November 19th, 2013
An ‘Iron-Triangle’ of Patients, Providers, and Payers?
Siqin Ye, MD
Several Cardiology Fellows who are attending AHA.13 in Dallas this week are blogging for CardioExchange. The Fellows include Vimal Ramjee, Siqin Ye, Seth Martin, Reva Balakrishnan, and Saurav Chatterjee. You can find the previous post here. For more of our AHA.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on […]
November 19th, 2013
An Insider’s Look at TACT
Gervasio Antonio Lamas, MD
TACT investigator Gervasio Lamas provides an inside look at how the TACT trial began, the controversial journey so far, and what he hopes it will accomplish.
November 19th, 2013
Another New Anticoagulant Works Well in AF Patients
Larry Husten, PHD
Edoxaban, a direct oral factor Xa inhibitor, is the latest in the series of new oral anticoagulants seeking to take over the troubled role of warfarin in clinical practice. The results of ENGAGE-AF-TIMI 48 were presented at the American Heart Association meeting in Dallas and published simultaneously in the New England Journal of Medicine. In the trial, more than […]
November 19th, 2013
TACT Substudy Suggests Possible Strong Benefit for Chelation in Diabetics
Larry Husten, PHD
One year ago the results of the TACT trial were published in JAMA, sparking an enormous controversy over the propriety of publishing a trial suggesting that chelation therapy might be beneficial in people with cardiovascular disease. Chelation therapy has long been a staple of alternative medicine, but until the publication of TACT it had received […]
November 19th, 2013
Does It Matter that I Miss Another Late-Breaking (“Heart-Breaking”) Session at AHA?
Reva Balakrishnan, MD, MPH
This Fellow needs to leave AHA early and wonders what she is missing.
November 18th, 2013
Super-Cells & Chimeras: Mission Impossible 5 or Transformative Approaches to New Heart?
Vimal Ramjee, MD
This cardiology fellow is stunned by some of the basic science reported at AHA.13.
November 18th, 2013
How to Have a Solid Foundation in Clinical Research and Data Analysis
Saurav Chatterjee, MD
A cardiology fellow at AHA gets advice from a more-established research clinician.